Practice Management News

Journal clubs in rheumatology are as pervasive as they are useful.

In the rapidly evolving landscape of investments, it is crucial for physicians to stay informed about alternative asset classes, such as cryptocurrency.

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more.

This year’s Congress of Clinical Rheumatology-East will celebrate the annual meeting’s 40th anniversary with banquets, record in-person attendance and a host of new presenters.

In a 3-2 vote, the Federal Trade Commission passed a final rule that bans new noncompete agreements with all workers in for-profit organizations.

In this video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, lays out the top stories out of the April issue, including the cover story centering on providers’ priorities regarding work-life balance.

Indications for the use of checkpoint inhibitors are ever expanding. However, even as these drugs have helped patients with cancer live longer, the emergence of various immune related adverse events limits their full potential in many.

I recently had the pleasure of attending a symposium at the Cleveland Clinic that featured an outstanding review of immune-related adverse events, and I was reminded of how far we have come in the decade since I first became involved in the evolution of this disease class.

When it comes to work-life balance, providers in the past skewed more toward work than life.

The power of biologics in treating rheumatoid arthritis bested the benefits of the Mediterranean diet in this year’s RheumMadness tournament, coming out ahead as the most “practically perfect” nugget to carry forward into practice.